Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting

v3.10.0.1
Segment Reporting
 6 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
16.
Segment Reporting
 
In accordance with FASB ASC 280, “
Segment Reporting
,” the Company discloses financial and descriptive information about its reportable segments. The Company operates in two segments, iBio, Inc. and iBio CDMO. These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Please note that certain totals may not sum due to rounding.
 
Three Months Ended December 31, 2018 (in thousands)
 
iBio, Inc.
 
 
iBio CDMO
 
 
Eliminations
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues – external customers
 
$
651
  
 
$
-
  
 
$
-
  
 
$
651
  
Revenues – intersegment
 
 
400
  
 
 
696
  
 
 
(1,096
)
 
 
-
  
Research and development
 
 
1,541
  
 
 
535
  
 
 
(803
)
 
 
1,273
  
General and administrative
 
 
1,202
  
 
 
2,483
  
 
 
(292
)
 
 
3,393
  
Operating loss
 
 
(1,692
)
 
 
(2,323
)
 
 
-
  
 
 
(4,015
)
Interest expense
 
 
-
  
 
 
(476
)
 
 
-
  
 
 
(476
)
Interest and other income
 
 
17
  
 
 
4
  
 
 
-
  
 
 
21
  
Consolidated net loss
 
 
(1,675
)
 
 
(2,795
)
 
 
-
  
 
 
(4,470
)
Total assets
 
 
40,770
  
 
 
12,676
  
 
 
(13,143
)
 
 
40,303
  
Fixed assets, net
 
 
3
  
 
 
24,809
  
 
 
-
  
 
 
24,812
  
Intangible assets, net
 
 
1,498
  
 
 
-
  
 
 
-
  
 
 
1,498
  
Depreciation expense
 
 
-
  
 
 
364
  
 
 
-
  
 
 
364
  
Amortization of intangible assets
 
 
68
  
 
 
-
  
 
 
-
  
 
 
68
  
 
Three Months Ended December 31, 2017 (in thousands)
 
iBio, Inc.
 
 
iBio CDMO
 
 
Eliminations
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues – external customers
 
$
153
 
 
$
-
 
 
$
-
 
 
$
153
 
Revenues – intersegment
 
 
330
 
 
 
96
 
 
 
(426
)
 
 
-
 
Research and development
 
 
676
 
 
 
482
 
 
 
(165
)
 
 
993
 
General and administrative
 
 
1,221
 
 
 
1,694
 
 
 
(328
)
 
 
2,587
 
Operating loss
 
 
(1,414
)
 
 
(2,013
)
 
 
-
 
 
 
(3,427
)
Interest expense
 
 
-
 
 
 
(479
)
 
 
-
 
 
 
(479
)
Interest and other income
 
 
4
 
 
 
2
 
 
 
-
 
 
 
6
 
Consolidated net loss
 
 
(1,410
)
 
 
(2,490
)
 
 
-
 
 
 
(3,900
)
Total assets
 
 
21,563
 
 
 
26,002
 
 
 
(12,725
)
 
 
34,840
 
Fixed assets, net
 
 
7
 
 
 
25,282
 
 
 
-
 
 
 
25,289
 
Intangible assets, net
 
 
1,702
 
 
 
-
 
 
 
-
 
 
 
1,702
 
Depreciation expense
 
 
-
 
 
 
341
 
 
 
-
 
 
 
341
 
Amortization of intangible assets
 
 
84
 
 
 
-
 
 
 
-
 
 
 
84
 
 
Six Months Ended December 31, 2018 (in thousands)
 
iBio, Inc.
 
 
iBio CDMO
 
 
Eliminations
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues – external customers
 
$
696
  
 
$
-
  
 
$
-
  
 
$
696
  
Revenues – intersegment
 
 
764
  
 
 
753
  
 
 
(1,517
)
 
 
-
  
Research and development
 
 
2,099
  
 
 
1,122
  
 
 
(824
)
 
 
2,397
  
General and administrative
 
 
2,239
  
 
 
4,717
  
 
 
(692
)
 
 
6,264
  
Operating loss
 
 
(2,878
)
 
 
(5,087
)
 
 
-
  
 
 
(7,965
)
Interest expense
 
 
-
  
 
 
(952
)
 
 
-
  
 
 
(952
)
Interest and other income
 
 
40
  
 
 
8
  
 
 
-
  
 
 
48
  
Consolidated net loss
 
 
(2,838
)
 
 
(6,031
)
 
 
-
  
 
 
(8,869
)
Total assets
 
 
40,770
 
 
 
12,676
 
 
 
(13,143
)
 
 
40,303
 
Fixed assets, net
 
 
3
 
 
 
24,809
 
 
 
-
 
 
 
24,812
 
Intangible assets, net
 
 
1,498
 
 
 
-
 
 
 
-
 
 
 
1,498
 
Depreciation expense
 
 
1
  
 
 
723
  
 
 
-
 
 
 
724
 
Amortization of intangible assets
 
 
151
  
 
 
-
  
 
 
-
 
 
 
151
 
 
Six Months Ended December 31, 2017 (in thousands)
 
iBio, Inc.
 
 
iBio CDMO
 
 
Eliminations
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
237
 
 
$
38
 
 
$
-
 
 
$
275
 
Revenues – intersegment
 
 
631
 
 
 
306
 
 
 
(937
)
 
 
-
 
Research and development
 
 
1,294
 
 
 
966
 
 
 
(282
)
 
 
1,978
 
General and administrative
 
 
2,320
 
 
 
3,392
 
 
 
(627
)
 
 
5,085
 
Operating loss
 
 
(2,746
)
 
 
(4,042
)
 
 
-
 
 
 
(6,788
)
Interest expense
 
 
-
 
 
 
(959
)
 
 
-
 
 
 
(959
)
Interest and other income
 
 
16
 
 
 
4
 
 
 
-
 
 
 
20
 
Consolidated net loss
 
 
(2,730
)
 
 
(4,997
)
 
 
-
 
 
 
(7,727
)
Total assets
 
 
21,563
 
 
 
26,002
 
 
 
(12,725
)
 
 
34,840
 
Fixed assets, net
 
 
7
 
 
 
25,282
 
 
 
-
 
 
 
25,289
 
Intangible assets, net
 
 
1,702
 
 
 
-
 
 
 
-
 
 
 
1,702
 
Depreciation expense
 
 
1
 
 
 
678
 
 
 
-
 
 
 
679
 
Amortization of intangible assets
 
 
169
 
 
 
-
 
 
 
-
 
 
 
169